OR WAIT null SECS
Click here to read the articles and download the PDF
A conversation with Matthew Bardell, managing director, nVentic, about a perhaps overlooked but useful strategic component of company performance and overall business benchmarks: inventory optimization.
Making sense of the accelerating trends and challenges—including store closings, pharmacy deserts, and the rise of polypharmacy.
Even as pharma technology evolves, and payers argue over reimbursement practices throughout healthcare, drug wholesaling is a thriving business.
February 15, 2024
There were no safety or efficacy issues identified in the FDA complete response letter for Lymphir, with no additional trials required.
Patients with severe frostbite who were administered Aurlumyn monotherapy experienced a significantly reduced risk of the need for amputation.
February 14, 2024
Augtyro was previously approved in November 2023 to treat locally advanced or metastatic ROS1-positive non-small cell lung cancer.
Onivyde (irinotecan liposome injection) in combination with oxaliplatin, fluorouracil, and leucovorin (NALIRIFOX) was found to improve overall survival in metastatic pancreatic adenocarcinoma.
Properly supporting market access for a newly launched product with a single indication is challenging. Doing so for multiple indications, or supporting subsequent indications, can have a compounding effect on the degree of difficulty for getting everything right.
Analysis explores where drug prices are derived from, and whether a holistic societal approach can help determine these products’ true value.
Bruce Phelan of Blue Fin discusses Novo Nordisk's purchase of Catalent manufacturing sites to increase its ability to meet the demand for the popular weight loss drug Wegovy.
February 13, 2024
Examination evaluates investigational stem cell interventions, including how the states have implemented their own policies when it comes to their uses.
The analysis notes that 60% of respondents were setting targets based on AI’s ability to either cut costs or boost productivity.
Roche and Repare came to terms on a deal in June 2022 to develop and commercialize camonsertib, which included a $125 million upfront payment and could have reached up to $1.2 billion based on clinical, regulatory, commercial, and sales milestones.